<SEC-DOCUMENT>0001157523-21-000483.txt : 20210421
<SEC-HEADER>0001157523-21-000483.hdr.sgml : 20210421
<ACCEPTANCE-DATETIME>20210421082816
ACCESSION NUMBER:		0001157523-21-000483
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210421
FILED AS OF DATE:		20210421
DATE AS OF CHANGE:		20210421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		21839630

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52415517.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div style="font-family: 'Times New Roman',Times,serif;">
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: center; font-weight: bold;">&#160; <font style="font-size: 16pt;">UNITED STATES</font></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
    <div style="font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: center;">For the month of April 2021</div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
    <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
    <div style="text-align: center;">(Address of principal executive office)</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center;">Form 20-F&#160; &#9744; Form 40-F&#160; &#9746;</div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div style="text-align: justify;">&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <div>&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: justify;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    &#160;
    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="text-align: center;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zfdab4c5276174f04a7776c30f0f5c3fb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div><a href="a52415517_ex991.htm">99.1</a></div>
          </td>
          <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify;"><a href="a52415517_ex991.htm">Press Release dated April 21, 2021.</a></div>
          </td>
        </tr>

    </table>
    <div style="text-align: center;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-top: 6pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; margin-top: 6pt; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z2ac3af64494642fbb861f7d749732a1d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>Date: April 21, 2021</div>
          </td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="font-style: italic;">/s/ Lisa Helbling</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>Lisa Helbling</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify;">&#160;</div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52415517_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--April 21, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that
            it has selected and retained LifeSci Advisors as investor relations agent of record. </p>
          <p> Jennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, &#8220;We are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important stage of our Company&#8217;s evolution. With over 500 clients
            under contract globally, we look forward to continuing our discovery and development of proprietary novel antibodies while providing CRO services to 70% of the top 20 pharma.&#8221; </p>
          <p> LifeSci Advisors (&#8220;LSA&#8221;), with over 250 employees and a local presence that spans, New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, provides life science companies comprehensive solutions to communications and investor
            outreach. Taking a partner approach, LSA increases client visibility within the investment community and educates investors on opportunities with its clients through non-deal roadshow planning and execution, KOL Events/R&amp;D Days, and
            corporate communications. </p>
          <p> <b>About ImmunoPrecise Antibodies Ltd.</b> </p>
          <p> IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The
            Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the
            Company&#8217;s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. For further information,
            visit <u>www.immunoprecise.com</u> or contact <u>solutions@immunoprecise.com</u> </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Investors: <br>
            LifeSci Advisors <br>
            John Mullaly <br>
            Email: jmullaly@lifesciadvisors.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
